Bivalirudin or heparin in primary angioplasty performed through the transradial approach: Results from a multicentre registry

European Heart Journal: Acute Cardiovascular Care

Volumn 3, Issue 3, 2014, Pages 268-274

  Sciahbasi, Alessandro ^a   Rigattieri, Stefano ^a   Cortese, Bernardo ^b   Belloni, Flavia ^c   Russo, Carmelo ^a   Ferraironi, Alessandro ^c   Tespili, Maurizio ^d   Angeletti, Chiara ^d   Ricci, Roberto ^c   Bondanini, Francesco ^a   Pugliese, Francesco Rocco ^a  

^a SANDRO PERTINI HOSPITAL   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c SPIRITO SANTO HOSPITAL   (Italy)

^d BOLOGNINI HOSPITAL   (Italy)

Author keywords

Bivalirudin; glycoprotein IIb IIIa inhibitors; primary PCI; transradial approach

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; FIBRINOGEN RECEPTOR; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PROCEDURES; PROSPECTIVE STUDY; REGISTER; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ANTITHROMBINS; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84908375632     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872613519331     Document Type: Article

References (26)

1. Lee MS, Liao H, Yang T, et al. Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials. Int J Cardiol 2011; 152; 369–374.
2. Bertrand OF, Jolly SS, Rao SV, et al. Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention. Am J Cardiol 2012; 110; 599–606.
3. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndrome. Circulation 2006; 114; 774–782.
4. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200–1206.
5. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218–2230.
6. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377: 2193–2204.
7. Agostoni P, Biondi-Zoccai GG, de Benedictis ML, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; Systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 2004; 44: 349–356.
8. Sciahbasi A, Pristipino C, Ambrosio G, et al. Arterial accesssite-related outcomes of patients undergoing invasive coronary procedures for acute coronary syndromes (from the ComPaRison of Early Invasive and Conservative Treatment in Patients With Non-ST-ElevatiOn Acute Coronary Syndromes [PRESTO-ACS] Vascular Substudy). Am J Cardiol 2009; 103: 796–800.
9. Mehta SR, Jolly SS, Cairns J, et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. J Am Coll Cardiol 2012; 60: 2490–2499.
10. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol 2012; 60: 2481–2489.
11. Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized trials of drug-eluting stents. N Engl J Med 2007; 356: 1020–1029.
12. The Thrombolysis In Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985; 312: 932–936.
13. D'Agostino RB. Tutorial in biostatistics-propensity score methodsfor bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265–2281.
14. Applegate RJ, Sacrinty MT, Kutcher MA, et al. Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention 1998–2003. Catheter Cardiovasc Interv 2006; 67: 556–562.
15. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619.
16. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362–e345.
17. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the guideline for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61: e179–e347.
18. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32; 2999–3054.
19. Hamon M, Rasmussen LH, Manoukian SV, et al. Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. EuroIntervention 2009; 5: 115–120.
20. MacHaalany J, Abdelaal E, Bataille Y, et al. Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention. Am J Cardiol 2012; 110: 1742–1748.
21. Baklanov DV, Kim S, Marso SP, et al. Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention. Circ Cardiovasc Interv 2013; 6: 347–353.
22. Bonello L, de Labriolle A, Roy P, et al. Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty. Cardiovasc Revasc Med 2009; 10: 156–161.
23. Chu WW, Kuchulakanti PK, Wang B, et al. Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction. Cardiovasc Revasc Med 2006; 7: 132–135.
24. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203–2216.
25. Hibbert B, MacDougall A, Labinaz M, et al. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. Circ Cardiovasc Interv 2012; 6: 805–812.
26. Cortese B, Limbruno U, Severi S, et al. Effect of prolonged bivalirudin infusion on ST-segment resolution following primary percutaneous coronary intervention (from the PROBIVIRI 2 study). Am J Cardiol 2011; 108:1220–1224.